Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02980510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

Study acronym: PANIRINOX
StatusCompleted
PhasePhase 2
SponsorUNICANCER
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Eligibility criteria expanded, about 30 words · Study description expanded, about 7 words · Site details revised at 1 of 6 sites · 1 more Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Study description expanded, about 7 words
    • Site details revised at 1 of 6 sites
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Dec 2024 to Dec 2025 Completion date: Jan 2025 to Jan 2026v15 Show 1 more changeShow less
    • Completion date: Jan 2025 to Jan 2026
  3. Re-verified, no change to tracked fieldsv14
  4. Primary completion date: Dec 2023 to Dec 2024 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 209 to confirmed 219 · Completion date: Jan 2024 to Jan 2025 · 1 morev13 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 209 to confirmed 219
    • Completion date: Jan 2024 to Jan 2025
    • Site details revised at 6 of 6 sites
  5. Re-verified, no change to tracked fieldsv12
Show 10 earlier versionsHide 10 earlier versions
  1. Eligibility criteria shortened, about 3 wordsv11 See this version in full on ClinicalTrials.gov ↗
  2. Primary completion date: Dec 2020 to Dec 2023 Study description shortened, about 2 wordsv10 Show 1 more changeShow less
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Suspended to Recruiting Site details revised at 6 of 6 sites · Eligibility criteria shortened, about 1 wordv9 Show 2 more changesShow less
    • Site details revised at 6 of 6 sites
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Recruiting to Suspended Sponsor's reason: Temporary suspension since March 13 due to COVID-19 pandemic Site details revised at 6 of 6 sitesv8 Show 1 more changeShow less
    • Site details revised at 6 of 6 sites
  5. Interventions: Panitumumab, oxaliplatin, folinic acid, 5fluoruracil (Drug), Panitumumab, oxaliplatin, folinic acid, 5fluoruracil, irinotecan (Drug) to Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil (Drug), Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan (Drug) Eligibility criteria expanded, about 8 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study title expanded, about 2 wordsv6 See this version in full on ClinicalTrials.gov ↗
  7. Primary completion date: Jun 2018 to Dec 2020 Study description expanded, about 50 words · Study title shortened, about 13 wordsv5 Show 2 more changesShow less
    • Study description expanded, about 50 words
    • Study title shortened, about 13 words

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv4
  9. Trial status: Not Yet Recruiting to Recruiting Site details revised at 6 of 6 sitesv3 Show 1 more changeShow less
    • Site details revised at 6 of 6 sites
  10. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
UNICANCER
98 trials monitored
See 7 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.
Trial Details
NCT Number NCT02980510
Lead Sponsor UNICANCER
Conditions Metastatic Colorectal Cancer
Enrollment 219 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov